
Be Aware of Aggregators in the Search for Potential Human *ecto-5'*-nucleotidase Inhibitors

As described in the manuscript, 49 known *ecto*-5′-NT inhibitors (here named <u>LIT-01</u> to <u>LIT-</u> <u>49</u>) were grouped in three clusters, according to Aggregator Advisor tool [1] results:

- **Cluster <u>1</u> (Table S1)**: compounds that (i) were not found to be similar to any previously reported aggregator and (ii) have calculated LogP values lower than 3.
- **Cluster 2** (Table S2): compounds that (i) were found to be similar to one previously reported aggregator and (ii) have calculated LogP values lower than 3.
- **Cluster <u>3</u> (Table S3)**: compounds that (i) were not found to be similar to any previously reported aggregator and (ii) have calculated LogP values higher than 3.

Compound (ID)	Structure	Ref.
<u>LIT-01</u>		[2]
<u>LIT-02</u>		[3]
<u>LIT-03</u> to <u>LIT-05</u>	$N = N_{HO} O_{O} O_{O}$	[3]
<u>LIT-)06</u>	$\begin{array}{c} \underline{\text{Lit-us}} : X=S \text{ and } R = Be2^{-1} \\ O \\ $	[3]
<u>LIT-07</u>		[3]
<u>LIT-08</u>	HO N N H	[4]
<u>LIT-09</u>	HO O'L O'L O'L O'L O'L O'L O'L O'L O'L O'	[4]

Table S1. Chemical structures of compounds grouped as Cluster 1 (LIT-01 to LIT-12).



¹Values calculated using Aggregator Advisor Tool (online available at http://advisor.bkslab.org/) [1].

²Bez: benzyl group

Table S2. Chemical structures of compounds grouped as **Cluster <u>2</u>** (<u>LIT-13</u> to <u>LIT-44</u>), chemical structures of some previously reported aggregators, and the corresponding Tanimoto similarity index values (%), obtained using Aggregator Advisor tool.

Compound (ID)	Structure	Ref.	Previously reported aggregator (structure)	Ref.	Tanimoto similarity index value (%) ¹
<u>LIT-13</u>	$\substack{H_2N, \downarrow, \downarrow,$	[5]	H HO OH	[6]	75
<u>LIT-14</u>	$H_2N \bigvee_{N \searrow N}^{N = N_1, \dots, O} H_0 \xrightarrow{(N^1 \cup O)}_{OH} O (N^1 \cup $	[7]	H H HO OH	[6]	74
<u>LIT-15</u>	$\begin{array}{c} \underset{\substack{N = \\ H_2N} \\ H_2N \\ N \\$	[2]	H H HO OH	[6]	73
<u>LIT-16</u> to <u>LIT-23</u>	$\begin{array}{c} \underset{R_2}{\overset{R_1}{\underset{N}{\underset{N}{\underset{N}{\underset{N}{\underset{N}{\underset{N}{\underset{N}{$	[3]	$ \underbrace{ \begin{array}{c} \begin{array}{c} \\ \\ \end{array} \end{array} }^{H} \underbrace{ \begin{array}{c} \\ \\ \\ \end{array} }^{N} \underbrace{ \\ \\ \\ \end{array} }^{N} \underbrace{ \begin{array}{c} \\ \\ \\ \end{array} }^{N} \underbrace{ \\ \\ \\ \\ \end{array} }^{N} \underbrace{ \begin{array}{c} \\ \\ \\ \\ \end{array} }^{N} \underbrace{ \\ \\ \\ \\ \\ \end{array} }^{N} \underbrace{ \\ \\ \\ \\ \\ \\ \\ \end{array} }^{N} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ $	[6]	71 to 78
<u>LIT-24</u> to <u>LIT-28</u>	$\begin{array}{c} \underbrace{\Pi - 24}_{N, N} R = H \\ \underline{\Pi - 24}_{N, N} R = H \\ \underline{\Pi - 25}_{N, N} R = R \\ \underline{\Pi - 25}_{N, N} R = NH_2 \\ \underline{\Pi - 27}_{N, N} R = SO_2 NH_2 \\ \underline{\Pi - 28}_{N, N} R = NO_2 \end{array}$	[3]	H H H HO OH	[6]	71 to 74

Molecules **2018**, 23, x FOR PEER REVIEW

<u>LIT-29</u>	$ \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \\ \\ \end{array} \end{array} \\ \\ \\ \\ \\ \\ \end{array} \\ \\ \\ \\ \\ \\ \\ $	[3]	$\mathbf{r}_{\mathbf{N}} = \mathbf{r}_{\mathbf{N}} = $	[6]	75
<u>LIT-30</u> to <u>LIT-33</u>	$H = H \text{ and } R_2 = CI$ $H = H \text{ and } R_2 = R$ $H = H \text{ and } R_2 = R$ $H = H \text{ and } R_2 = R$ $H = H \text{ and } R_2 = R$ $H = H \text{ and } R_2 = R$	[3]	$\mathbf{r}_{\mathbf{N}} = \mathbf{r}_{\mathbf{N}} = $	[6]	70 or 71
<u>LIT-34</u> to <u>LIT-36</u>	$H_{2N} \xrightarrow{N}_{H \to N} H_{O} \xrightarrow{N}_{OH} H_{O} \xrightarrow{P}_{R_{2}} H_{O} \xrightarrow{P}_{R$	[3]	$ = \begin{array}{c} \begin{array}{c} H \\ H $	[6]	71
<u>LIT-37</u> to <u>LIT-40</u>	$\begin{array}{c} \begin{array}{c} & & & \\ & & $	[3]	$ \qquad \qquad$	[6]	72 to 74
<u>LIT-41</u>	$LIT-39: R_1 = R_2 = CH_3$ $LIT-40: R_1 = R_2 = CH_2CH_3$ $\downarrow 0 \qquad $	[4]	NH O HN OO O	[6]	74
<u>LIT-42</u>	CI C	[4]	NH O HN OOL O	[6]	71
<u>LIT-43</u>	CI NH2 CI NH2 NH2 NH2	[4]		[6]	75
<u>LIT-44</u>	но он он он он он он он	[8]	он о но он он но он он он он		100

¹Values calculated using Aggregator Advisor Tool (online available at *http://advisor.bkslab.org/*) [1].

²Phe: phenyl group

³Bez: benzyl group

Compound (ID)	Structure	Ref.	Calculated LogP value ¹
<u>LIT-45</u>	H H O=S=O O ⁻	[9]	3.1
<u>LIT-46</u>	C C C C C C C C C C C C C C C C C C C	[9]	4.3
<u>LIT-47</u>	0 ⁵ N ^{,0} Н ОН ОН О И О И О И О И О	[4]	3.3
<u>LIT-48</u>		[4]	4.4
<u>LIT-49</u>	O N N N O S NH2	[4]	5.1

Table S3. Chemical structures of compounds grouped as **Cluster <u>3</u>** (<u>LIT-45</u> to <u>LIT-49</u>), and their corresponding calculated LogP values, obtained using Aggregator Advisor tool.

References

- Irwin, J. J.; Duan, D.; Torosyan, H.; Doak, A. K.; Ziebart, K. T.; Sterling, T.; Tumanian, G.; Shoichet, B. K. An Aggregation Advisor for Ligand Discovery. *J. Med. Chem.* 2015, *58*, 7076–7087, doi:10.1021/acs.jmedchem.5b01105.
- Knapp, K.; Zebisch, M.; Pippel, J.; El-Tayeb, A.; Müller, C. E.; Sträter, N. Crystal structure of the human ecto-5'-nucleotidase (CD73): Insights into the regulation of purinergic signaling. *Structure* 2012, 20, 2161–2173, doi:10.1016/j.str.2012.10.001.
- Bhattarai, S.; Freundlieb, M.; Pippel, J.; Meyer, A.; Abdelrahman, A.; Fiene, A.; Lee, S.-Y.; Zimmermann, H.; Yegutkin, G. G.; Sträter, N.; El-Tayeb, A.; Müller, C. E. α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto -5'-Nucleotidase (CD73) Inhibitors. *J. Med. Chem.* 2015, *58*, 6248–6263, doi:10.1021/acs.jmedchem.5b00802.
- Ripphausen, P.; Freundlieb, M.; Brunschweiger, A.; Zimmermann, H.; Müller, C. E.; Bajorath, J. Virtual Screening Identifies Novel Sulfonamide Inhibitors of ecto -5'-Nucleotidase. *J. Med. Chem.* 2012, 55, 6576– 6581, doi:10.1021/jm300658n.
- 5. Freundlieb, M.; Zimmermann, H.; Müller, C. E. A new, sensitive ecto-5???-nucleotidase assay for compound screening. *Anal. Biochem.* 2014, 446, 53–58, doi:10.1016/j.ab.2013.10.012.
- Ferreira, R. S.; Simeonov, A.; Jadhav, A.; Eidam, O.; Mott, B. T.; Keiser, M. J.; McKerrow, J. H.; Maloney, D. J.; Irwin, J. J.; Shoichet, B. K. Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. *J. Med. Chem.* 2010, *53*, 4891–4905, doi:10.1021/jm100488w.
- 7. Iqbal, J.; Jirovsky, D.; Lee, S. Y.; Zimmermann, H.; M??ller, C. E. Capillary electrophoresis-based nanoscale assays for monitoring ecto-5???-nucleotidase activity and inhibition in preparations of

¹Values calculated using Aggregator Advisor Tool (online available at http://advisor.bkslab.org/) [1].

recombinant enzyme and melanoma cell membranes. *Anal. Biochem.* 2008, 373, 129–140, doi:10.1016/j.ab.2007.09.028.

- Braganhol, E.; Tamajusuku, A. S. K.; Bernardi, A.; Wink, M. R.; Battastini, A. M. O. Ecto-5'nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line. *Biochim. Biophys. Acta - Gen. Subj.* 2007, 1770, 1352–1359, doi:10.1016/j.bbagen.2007.06.003.
- Baqi, Y.; Lee, S.; Iqbal, J.; Ripphausen, P.; Lehr, A.; Scheiff, A. B.; Zimmermann, H.; Bajorath, J.; Muller, C. E. Development of Potent and Selective Inhibitors of ecto -5'-Nucleotidase Based on an Anthraquinone Scaffold. *J. Med. Chem.* 2010, *53*, 2076–2086, doi:10.1021/jm901851t.